As of November 6, 2026, Cue Biopharma, Inc. is a publicly traded company (Nasdaq: CUE). The largest holder reporting an active stake on Schedule 13D is Shao-Lee Lin, the executive officer and a director, at 6.2%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Mark E. Strome (8.5%), Driehaus Capital Management LLC (6.96%) (Schedule 13D, August 21, 2026).
Is this your company?
About to sign with, pay or invest in Cue Biopharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Cue Biopharma, Inc. a real, registered company?
- Cue Biopharma, Inc. files with the SEC under CIK 1645460 (its SEC filings).
- Its shares are listed under the ticker CUE on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Somerville, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Cue Biopharma, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Sumita Ray, Corporate Secretary (Form 8-K filed 2026-06-02). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Mark E. Strome (filed 2026-10-08).
Who are Cue Biopharma, Inc.'s owners and officers?
Cue Biopharma, Inc.: incorporated in Delaware; business address in Somerville, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-08).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-07-22)
- : Executive Officer (Form D, 2026-07-22)
- : Executive Officer (Form D, 2026-07-22)
- : Director (Form D, 2026-07-22)
- : Director (Form D, 2026-07-22)
- : Director (Form D, 2026-07-22)
- : Director (Form D, 2026-07-22)
- : Executive Officer (Form D, 2026-07-22)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-08 | Mark E. Strome | 8.5% |
| Schedule 13D, 2026-08-21 | Shao-Lee Lin | 6.2% |
| Schedule 13G, 2026-08-14 | Driehaus Capital Management LLC | 6.96% |
Questions about who owns Cue Biopharma, Inc.
Who owns Cue Biopharma, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Cue Biopharma, Inc.: Mark E. Strome (8.5%, Schedule 13G/A, filed 2026-10-08), Driehaus Capital Management LLC (6.96%, Schedule 13G, filed 2026-08-14) and Shao-Lee Lin (6.2%, Schedule 13D, filed 2026-08-21).
Who are the largest shareholders of Cue Biopharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Cue Biopharma, Inc. on this page are Mark E. Strome (8.5%), Driehaus Capital Management LLC (6.96%) and Shao-Lee Lin (6.2%).
When did Mark E. Strome buy into Cue Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Mark E. Strome on this page is the Schedule 13G/A, filed 2026-10-08, reporting 8.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Cue Biopharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cue Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cue Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-02 | Sumita Ray | Corporate Secretary | appointed | 2026-06-01 |
| Form 8-K, 2026-06-02 | Michael Meluzio | Vice President, Principal Accounting Officer | appointed | 2026-06-01 |
| Form 8-K, 2026-05-01 | Lee Lin | President and Chief Executive Officer | appointed |
Which insiders own Cue Biopharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 694,908 shares (9.6% of shares outstanding) (Form 4, 2026-10-14).
- , the chief executive and a director: 164,578 shares (2.3% of shares outstanding) (Form 4, 2024-12-18).
- , the chief legal compliance officer: 116,701 shares (1.6% of shares outstanding) (Form 4, 2026-10-14).
- , the vice president and prin. accounting officer: 47,817 shares (0.66% of shares outstanding) (Form 4, 2026-10-14).
- , the chief medical officer: 31,500 shares (0.43% of shares outstanding) (Form 4, 2026-07-15).
Shares outstanding: 7,264,414 as of 2026-08-12, from the company's latest SEC cover page.
How much has Cue Biopharma, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-07-22 | $50M | $50M |
| Form D, 2026-05-14 | $30M | $30M |
| Form D, 2022-11-21 | $30M | $30M |
Keep reading
More on Cue Biopharma, Inc. and the records around it.
Cue Biopharma, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Aug 2026
- Company profile and every filing Jul 2026
- Form D filing Jul 2026
- Form D filing May 2026
Companies that share a holder
- Mark E. Strome also filed stake reports on 2 other companies: HeartBeam, Inc. (Aug 2026), Zivo Bioscience (Feb 2026)
- DRIEHAUS CAPITAL MANAGEMENT LLC also filed stake reports on 16 other companies: Cardinal Infrastructure Group Inc. (Aug 2026), Definium Therapeutics, Inc. (Aug 2026), Frequency Electronics, Inc. (Aug 2026)
Related pages
Funding and filing historyLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/cue-biopharma-inc